News Releases
Monsanto Announces Record 11 Project Advancements in Annual Research and Development Pipeline Update
ST. LOUIS, Jan. 6, 2010 /PRNewswire-FirstCall/
— This year’s annual research and development (R&D) pipeline update marks many firsts for Monsanto Company (NYSE: MON). Among the record 11 project advancements are the first biotechnology product with a direct consumer dietary benefit and two of the largest commercial product launches in the company’s history…
…Monsanto’s SDA omega-3 soybeans also advanced to Phase 4. SDA omega-3 soybeans offer a sustainable, land-based source of SDA that readily converts to the heart-healthy omega-3 fatty acid found in fish oil. Last year, the United States Food and Drug Administration (FDA) issued a Generally Recognized As Safe notice affirming that the SDA omega-3 soybean oil could be used in a variety of foods. Food companies can now formulate and test the oil from SDA omega-3 soybeans in food products for future launch. Clinical studies have shown that consumption of SDA omega-3 soybean oil significantly raises blood levels of the heart-healthy omega-3 fatty acid EPA, also found in fish and fish oils.
See earlier post Omega 3 enhanced soybeans with SDA
